Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Preleukemia

Myelodysplastic Syndromes

Neoplasms by Histologic Type

Hematologic Diseases

Bone Marrow Diseases

Precancerous Conditions

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Hartmut Döhner, Prof. Dr.

Armin Zebisch, Prof. Dr.

David Nachbaur, Prof. Dr.

Michael Girschikofsky, Dr.

Clemens Schmitt, Prof.

Bernd Hartmann, Dr.

Richard Greil, Prof. Dr.

Elisabeth Koller, Dr.

Manfred Welslau, Dr.

Daniel Schöndube, Dr.med.

Annette Dieing, Dr.

Maike De Wit, Prof. Dr. med.

Jörg Westermann, PD Dr.

Joerg-Christian Rath, Dr.

Stefan Lukic, Dr.

Roland Schroers, Prof. Dr.

Lino Teichmann, Dr.

Jürgen Krauter, Prof. Dr.

Bernd Hertenstein, Prof. Dr. med.

Helga Bernhard, Prof. Dr. med.

Darina Kodzahbasheva, Dr.

Ulrich Germing, Prof.

Stefanie Groepper, Dr.

Peter Reimer, Prof. Dr.

Swen Wessendorf, PD Dr.

Angela Krackhardt, Prof. Dr.

Hans Günter Derigs, Prof. Dr. med.

Michael Lübbert, Prof. Dr.

Maisun Abu Samra, Dr.

Volker Runde, Prof. Dr. med.

Annamaria Brioli, Dr.

Martin Bommer, PD Dr.

Gerald Wulf, Prof. Dr.

Walter Fiedler, Prof. Dr.

Hans Salwender, Dr.

Ahmet Elmaagacli, Prof.

Alexander Baraniskin, Dr.

Huesameddin Yildirim, Dr.

Daniela Doerfel, Dr.

Felicitas Thol, PD Dr.

Uwe Martens, Prof. Dr.

Dirk Strumberg, Prof. Dr.

Joerg Bittingbring, Dr.

Gerhard Held, Prof.

Martin Bentz, Prof. Dr.

Martina Gnadler

Ali Nuri Hünerlitürkoglu, Dr.

Christian Bogner, Dr.

Stephan Kremers, Dr. med.

Frank Hartmann, Prof. Dr. med.

Martin Hoffmann, Dr.

Friederike Wortmann, Dr.

Monika Schwalenberg, Dr.

Ana Maria Waldleben

Christian Plate, Dr.

Michael Kuehn, Dr.

Mohammad Wattad, Dr.

Hans-Joachim Tischler, Dr.

Holger Hebart, Prof. Dr. med.

Jan Schröder, Dr.

Katharina Götze, Prof. Dr.

Thomas Wehler

Irmgard Dresel, Dr.

Frank Griesinger, Prof. Dr.

Andreas Voss, Dr.

Thomas Südhoff, Prof. Dr.

Su Hyeon Kim, Dr.

Michael Klein, Dr.

Hendrik Poeck, Prof. Dr.

Julian Alexis Topaly

Stephan Kremers, Dr.

Detlev Kohl, Dr

Jan Schleicher, Dr. med.

Jochen Greiner, Prof. Dr.

Claudio Denzlinger, Prof. Dr.

Thomas Kubin, Dr. med.

Rolf Mahlberg, Dr. med.

Iordanis Deligiannis, Dr.

Claudia Lengerke, Prof.

Konstanze Döhner, Prof. Dr.

Paul Graf La Rosee, Prof. Dr.

Heiko Hütten

Silke Schostok, Dr.

This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms

Investigator's sites: 60-70 sites in Germany and Austria

Estimated duration of observation of an individual patient:

10 years maximum

Objectives

* To register all patients with acute myeloid leukemia and related precursor neoplasms, acute leukemia of unambiguous lineage, with higher risk myelodysplastic syndromes (MDS with excess blasts 2), and with myeloid neoplasms with germline predisposition, newly diagnosed or relapsed/refractory in all participating centers (completeness)
* To perform timely analyses of disease-related genetic markers (incidences, treatment recommendations)
* To assess patient and family history, clinical characteristics and outcome data (event-free survival \[EFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\])
* To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)
* To store biosamples from all patients (e.g., bone marrow, blood, plasma, normal tissue, e.g., skin biopsy, buccal swap, finger nails, hairs, or sputum)
* To assess quality of life

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project

To perform timely analyses of disease-related genetic markers (according to WHO 2008 classification) (incidences, treatment recommendations)

To assess patient and family history, patient characteristics and outcome data (event-free survival \[EFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\])

Quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, socioeconomics, and demographics according to Messerer D et al (2008) initially, in first CR, one year, 3 and 5 years after initial diagnosis.

Geographical representation of patients through collection of patients zip codes

University of Ulm

Prof. Dr.

Spots Global Cancer Trial Database for biology and outcome